TDC
VRCA icon

Thompson Davis & Co’s Verrica Pharmaceuticals VRCA Stock Holding History

Thompson Davis & Co’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$5K Buy
+30
New +$5.12K 0.01% 578

Other funds holding VRCA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
CI
Conning Inc Hartford, Connecticut $3.34B AUM 25.19% 1-Year Est. Return

Thompson Davis & Co's VRCA Position: Q3 2018 in Review

Thompson Davis & Co opened a new position in Verrica Pharmaceuticals (VRCA) in Q3 2018: 30 shares worth $5K. The stake represents 0.01% of the portfolio and ranks #578 among its holdings.

45 funds tracked by Wall St. Rank hold VRCA as of Q3 2018.

  • Thompson Davis & Co held 30 shares of Verrica Pharmaceuticals worth $5K as of Q3 2018.
  • Verrica Pharmaceuticals was a new Thompson Davis & Co position in Q3 2018.
  • Verrica Pharmaceuticals made up 0.01% of Thompson Davis & Co's portfolio in Q3 2018, its #578 holding.
  • 45 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.